| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
148,092 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$4,955,193 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
154,765 |
|
|
| Total
Value |
$4,955,193 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2024-06-04 |
32,917 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
182 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 8
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-01-17 |
4 |
AS |
$13.93 |
$97,510 |
D/D |
(7,000) |
4,386 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2007-12-10 |
4 |
AS |
$10.03 |
$80,240 |
D/D |
(8,000) |
9,233 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-07-01 |
4 |
AS |
$59.56 |
$243,063 |
D/D |
(4,066) |
37,950 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-09-04 |
4 |
AS |
$69.00 |
$621,000 |
D/D |
(9,000) |
37,950 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-12-02 |
4 |
AS |
$70.14 |
$631,273 |
D/D |
(9,000) |
37,950 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-03-03 |
4 |
AS |
$80.32 |
$642,530 |
D/D |
(8,000) |
64,273 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-05-18 |
4 |
AS |
$130.00 |
$4,430,140 |
D/D |
(34,078) |
41,507 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-05-29 |
4 |
AS |
$126.15 |
$199,065 |
D/D |
(1,578) |
35,624 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-06-01 |
4 |
AS |
$124.16 |
$489,811 |
D/D |
(3,945) |
31,679 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-06-05 |
4 |
AS |
$122.30 |
$201,669 |
D/D |
(1,649) |
28,229 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-11-16 |
4 |
AS |
$104.30 |
$2,085,918 |
D/D |
(20,000) |
28,229 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-03-02 |
4 |
AS |
$86.12 |
$398,120 |
D/D |
(4,623) |
49,688 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-05-23 |
4 |
AS |
$87.07 |
$328,184 |
D/D |
(3,769) |
58,644 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-05-31 |
4 |
AS |
$89.35 |
$1,873,126 |
D/D |
(20,841) |
50,394 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-06-06 |
4 |
AS |
$89.14 |
$146,992 |
D/D |
(1,649) |
46,944 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-08-01 |
4 |
AS |
$99.33 |
$397,320 |
D/D |
(4,000) |
42,944 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-01-09 |
4 |
AS |
$90.00 |
$450,000 |
D/D |
(5,000) |
18,100 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-02-28 |
4 |
AS |
$94.00 |
$2,820,000 |
D/D |
(30,000) |
30,347 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-01 |
4 |
AS |
$94.50 |
$472,500 |
D/D |
(5,000) |
25,347 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-06 |
4 |
AS |
$93.32 |
$214,916 |
D/D |
(2,303) |
20,761 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2017-03-16 |
4 |
AS |
$91.96 |
$182,908 |
D/D |
(1,989) |
14,471 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-04-23 |
4 |
AS |
$82.15 |
$908,497 |
D/D |
(11,059) |
62,543 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-06-22 |
4 |
AS |
$99.00 |
$990,005 |
D/D |
(10,000) |
51,070 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-03-27 |
4 |
AS |
$90.00 |
$9,000 |
D/D |
(100) |
60,983 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2019-04-01 |
4 |
AS |
$89.00 |
$1,199,097 |
D/D |
(13,473) |
47,510 |
0 |
- |
|
182 Records found
|
|
Page 3 of 8 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
